Page 6 - Binding Affinity News Today

A recent study investigated ‘targets’ in the poxvirus and identified the protein residues active in MPV, following which eight potential anti-viral drugs were proposed.

Researchers explored how effectively nanotechnology-based novel and potential vaccines, drugs, and monoclonal antibodies could combat the current and yet to emerge SARS-CoV-2 variants.

Researchers assessed highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro.

In a new study, researchers developed bispecific-antibodies (bsAbs) against SARS-CoV-2 Omicron sub-lineages.

Researchers determined the cryo-electron microscopic (cryo-EM) structures of engineered angiotensin-converting enzyme 2 (ACE2) receptor traps.

Researchers evaluated all the features, especially the antigenic properties and transmission potential of SARS-CoV-2 Omicron sub-variant BA.2.75.

Scientists hypothesize that the GNA affinity resin would remain effective against SARS-CoV-2 variants.

Researchers evaluated all the features, especially the antigenic properties and transmission potential of SARS-CoV-2 Omicron sub-variant BA.2.75.

In a recent study posted to the medRxiv* pre-print server, Australian researchers comprehensively investigated the impact of 39 receptor-binding-domain (RBD) mutations in six severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and variants of interest (VOIs).

Scientists measured the quantity and binding affinity (avidity) of antibodies against five different viral proteins.